Data will be released after the AIM2CERV interim analysis only if the trial is halted early because of overwhelming efficacy relative to the expectations of the trial designers.
In the more likely case where the trial continues to the final analysis as planned, the decision to continue the trial will be the only info provided to investors (or to the company itself).
Market Data 
Markets 
AI
